189 related articles for article (PubMed ID: 30693647)
1. The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment.
Wcisło-Dziadecka D; Grabarek B; Kruszniewska-Rajs C; Strzałka-Mrozik B
Dermatol Ther; 2019 May; 32(3):e12843. PubMed ID: 30693647
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the clinical response and changes in the expression of TNF-α and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumab.
Wcisło-Dziadecka DL; Grabarek B; Kruszniewska-Rajs C; Gola JM; Simka K; Mazurek U
Adv Clin Exp Med; 2020 Feb; 29(2):235-241. PubMed ID: 32125100
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
5. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
[TBL] [Abstract][Full Text] [Related]
7. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
[TBL] [Abstract][Full Text] [Related]
8. Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment.
Zhou J; Shen JY; Liu LF; Chen JS; Dou TT; Zheng M; Cai SQ
Med Sci Monit; 2020 Jan; 26():e920371. PubMed ID: 31910201
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab.
Weber J; Keam SJ
BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
[TBL] [Abstract][Full Text] [Related]
12. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
Atalay S; van den Reek JMPA; den Broeder AA; van Vugt LJ; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MA; van de Kerkhof PCM; Groenewoud HMM; Kievit W; de Jong EMGJ
JAMA Dermatol; 2020 Apr; 156(4):393-400. PubMed ID: 32049319
[TBL] [Abstract][Full Text] [Related]
14. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
[TBL] [Abstract][Full Text] [Related]
16. When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab.
Damiani G; Conic RRZ; de Vita V; Costanzo A; Regazzini R; Pigatto PDM; Bragazzi NL; Pacifico A; Malagoli P
Dermatol Ther; 2019 Mar; 32(2):e12793. PubMed ID: 30515970
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
[TBL] [Abstract][Full Text] [Related]
18. IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment.
Bojko A; Ostasz R; Białecka M; Klimowicz A; Malinowski D; Budawski R; Bojko P; Droździk M; Kurzawski M
Hum Immunol; 2018 Apr; 79(4):213-217. PubMed ID: 29454820
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
Reich K; Pinter A; Lacour JP; Ferrandiz C; Micali G; French LE; Lomaga M; Dutronc Y; Henneges C; Wilhelm S; Hartz S; Paul C;
Br J Dermatol; 2017 Oct; 177(4):1014-1023. PubMed ID: 28542874
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Paul C; Griffiths CEM; van de Kerkhof PCM; Puig L; Dutronc Y; Henneges C; Dossenbach M; Hollister K; Reich K
J Am Acad Dermatol; 2019 Jan; 80(1):70-79.e3. PubMed ID: 29969700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]